Wolfe Research upgraded two prominent pharmaceutical companies to Outperform on August 13. The firm upgraded both Biogen Inc.
MLTX has faded since a mid-June rally on year-long hidradenitis suppurativa data and an August psoriatic arthritis readout, ...
Interim data from the 393-patient phase 3 CERVINO trial of etentamig (ABBV-383), a bispecific CD3 and BCMA-directed TCE, ...
Ken Griffin sees a bargain in Abbvie and increased his fund's position by buying 2.68 million shares of the healthcare giant.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results